NASDAQ: BVS · Industrial Applications and Services · 2 alerts · CIK 1665988
Share price
$10.46Close, Nov 16
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Bioventus Inc. filings on SEC EDGAR ↗
Bioventus Inc. filed its Q3 2026 10-Q reporting on the period ended September 26, 2026, noting 68,474,219 shares of Class A common stock outstanding. The company is currently undergoing a strategic alternatives review process while managing risks related to debt covenants under its 2025 Credit Agreement and potential FDA reclassification of its HA products.
Bioventus reported Q3 2026 worldwide revenue of $142.4 million, a 3% increase driven primarily by growth in its Pain Treatments business. The company achieved GAAP net income of $6.0 million and improved its diluted EPS to $0.08, while continuing to review potential strategic alternatives to maximize shareholder value.
Term
Q3 2026
“Bioventus delivered solid third-quarter results demonstrated by strong gross margin, operating cash flow and Adjusted EBITDA. We are encouraged by the underlying momentum across our key growth drivers and remain confident in our strategy, our portfolio and our ability to build Bioventus into a leading medtech company that delivers significant value for our shareholders, customers and employees.”
Rob Claypoole, Bioventus President and Chief Executive Officer